biopharma

As biotherapeutic modalities have diversified and production processes become more advanced, an evolution in purification strategies is also needed. Modern biotherapeutic purification must be capable of removing multiple types of impurities without compromising yield or quality, in a cost-effective manner. To meet these needs, many are turning to mixed-mode chromatography.

The BioRad.io podcast series is focused on R&D informatics, introducing you to people responsible for implementing systems and technologies to a diverse set of use-cases. Join us every month to see what you can learn.

A common challenge in scaling up cell and gene therapy production is monitoring for contaminants, such as Mycoplasma. Learn how ddPCR can help in this webinar.

For over 30 years, CHT Ceramic Hydroxyapatite Chromatography Media has been a trusted, proven purification solution for many biopharmaceutical manufacturing processes. CHT Media provides exceptional removal of impurities when other chromatography resins fall short. In this webcast, explore the essential facts and benefits of this chromatography technology.

In nature, mammalian extracellular vesicles (EVs) are vital for intercellular communication, immune responses, and cell removal. EVs also hold promise in diagnostics, therapeutics, and vaccine delivery due to their abundance and natural role as carriers. Explore how overcoming challenges in EV purification and precise RNA analysis methods can help unlock their potential applications.

Endotoxins are common impurities that pose safety risks in therapeutic protein preparations and are difficult to remove. See proven workflows and strategies.

Bispecific antibodies pose unique challenges in downstream processing. See how impurities were efficiently removed by mixed-mode chromatography in this webinar.

In recent years, biologics — drugs derived from living culture systems — have become increasingly significant in the fight against a plethora of conditions. Unfortunately, the efficiency of these drugs comes at a cost. A daily dose of a biologic drug costs, on average, 22 times more than conventional small-molecule drugs. Therefore, biosimilars are developed to make them more accessible. Lung cancer is an example where the development of biosimilars could increase treatment options available for patients.

Biotherapeutic antibody discovery is inherently challenging. Amongst the clinically proven technologies for antibody discovery is phage display — a technique utilized by one of the most recent and innovative solutions on the market: the Pioneer Antibody Discovery Platform.

The therapeutic potential of messenger RNA (mRNA) therapeutics has an unprecedented ability to target previously undruggable diseases. The poly(A) tail drives the therapeutic efficacy of the mRNA molecule. Using Droplet Digital PCR (ddPCR) technology to analyze poly(A) tail length and integrity yields unrivaled sensitivity, enabling developers to ensure high poly(A) tail integrity and, ultimately, functional therapeutic mRNAs.